ENTAEnanta Pharmaceuticals, Inc.
$12.10+9.2% 1Y
$12.10
$10.4752 weeks$16.85
The financials
Enanta Pharmaceuticals, Inc. by the numbers
Enanta Pharmaceuticals, Inc. (ENTA) reported revenue of $14M in Q3 2026 (quarter ended Jun 30, 2026), down 22% from the same quarter a year earlier. That came with net loss of $20M. For the full year FY2025, revenue was $65M (−3.4% year on year) and net income −$82M. The next results filing is expected around Nov 16, 2026, the same week as a year ago.
| Income statement | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Revenue | $14M | $18M | −22% |
| Operating income | −$17M | −$19M | n/a |
| Net income | −$20M | −$18M | n/a |
| Diluted EPS | −$0.67 | −$0.85 | n/a |